SCHEMBL4764208

SCHEMBL4764208

CSc1ccc(-c2cc3ccccc3c(Cl)n2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A3 P47895 1/20 0.40
▸ ADORA3 P0DMS8 4/20 0.40
▸ ADORA1 P30542 3/20 0.40
▸ ADORA2A P29274 2/20 0.40
▸ DHODH Q02127 1/20 0.40
▸ ADORA2B P29275 1/20 0.40
▸ SYK P43405 1/20 0.39
▸ ABCB1 P08183 1/20 0.39
▸ ABCC1 P33527 1/20 0.39
▸ ABCG2 Q9UNQ0 1/20 0.39
▸ ALDH1A1 P00352 4/20 0.38
▸ HPGD P15428 4/20 0.38
▸ KDM4E B2RXH2 4/20 0.38
▸ MAPT P10636 3/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ GLA P06280 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ L3MBTL1 Q9Y468 3/20 0.38
▸ MEN1 O00255 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4763818 0.84 HPGD (0.37) ADORA3ALDH1A1HPGDKDM4EMAPT
SCHEMBL31388225 0.81 MEN1 (0.55) ADORA3ADORA1ADORA2AALDH1A1HPGD
SCHEMBL786133 0.81 MEN1 (0.55) ADORA3ADORA1ADORA2AALDH1A1HPGD
SCHEMBL7258823 0.79 CYP19A1 (0.47) ADORA1ADORA2ADHODHALDH1A1HPGD
SCHEMBL4767456 0.79 AGTR1 (0.45) ALDH1A1HPGDKDM4EMAPTSMN1; SMN2
SCHEMBL4763954 0.78 NPC1 (0.58) ADORA3SYKALDH1A1HPGDKDM4E
SCHEMBL6001719 0.77 ABCB1 (0.50) ALDH1A3ADORA1DHODHABCB1ABCC1
SCHEMBL22201436 0.77 PRKCH (0.52) DHODHALDH1A1HPGDKDM4EMAPT
SCHEMBL6001420 0.77 PRKCH (0.44) ALDH1A3DHODHSYKALDH1A1HPGD
SCHEMBL28619679 0.76 CYP1A2 (0.44) ADORA1ADORA2AALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 — — EP disclosed
US-6875761-B2 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. (JP) 2005-04-05 — — US disclosed
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. 2004-10-14 — — US disclosed
US-6790844-B2 MUSCLE RELAXANTS; ANTISEROTONINE AGENT EISAI CO., LTD (JP) 2004-09-14 — — US disclosed
US-20020013460-A1 Condensed pyridine compound EISAI CO., LTD 2002-01-31 — — US disclosed
US-6340759-B1 ANTISPASMODIC AGENTS EISAI CO., LTD. (JP) 2002-01-22 — — US disclosed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013460-A1 Condensed pyridine compound MUSK, HTR1A, PAX3 ALDH1A3 3705/4885ADORA3 1533/4885ADORA1 675/4885
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives MUSK, HTR1A, RYR1 ALDH1A3 1345/4885ADORA3 377/4885ADORA1 196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback